ABNewswire - Press Release Distribution Service

Friday, April 26, 2024

Happy Breathing Launches its Easy-to-Use Baby Nasal Aspirator with Medical-grade Suction

Happy Breathing, a pioneering company in pediatric healthcare, is set to revolutionize the way parents care for their infants with the imminent launch of its innovative baby nasal aspirator. Designed by a Neonatal Respiratory Therapist, this hospital-grade suction device promises to provide immediate relief for infants suffering from nasal congestion, offering a safe and effective alternative to stressful hospital visits.

The Happy Breathing baby nasal aspirator results from extensive research and development aimed at addressing the challenges faced by parents dealing with infant respiratory illnesses. With three levels of gentle suction, parents can easily customize the device to meet their baby's specific needs, providing comfort and ease without damaging delicate mucous membranes.

One of the key features of the Happy Breathing baby nasal aspirator is its portability and convenience. The device is chargeable, eliminating the need for cords and allowing parents to use it on the go. The sleek and compact design ensures that the device can be easily carried in a travel case, making it ideal for use at home or while traveling.

Safety is paramount when it comes to infant healthcare, and the Happy Breathing baby nasal aspirator is designed with this in mind. Made from 100% BPA-free materials, the device is easy to clean and maintain, ensuring that it remains hygienic for repeated use. Additionally, the device comes with a 1-year warranty, providing parents with peace of mind knowing they are investing in a high-quality product.

The Happy Breathing baby nasal aspirator is designed to be easy to use, even for first-time parents. Its intuitive design allows parents to quickly and effectively clear their baby's airways, providing immediate relief from congestion. The device's simple operation means that parents can use it confidently, knowing that they are providing their baby with the necessary care.

Happy Breathing empowers parents to take proactive measures to manage their children's respiratory health. This innovative tool not only reduces the need for unnecessary emergency room visits but also significantly alleviates parental anxiety. Investing in Happy Breathing is essentially investing in children's well-being and their parents' peace of mind, making a substantial impact on pediatric healthcare.

"We understand the challenges that parents face when caring for their infants, especially when it comes to respiratory illnesses," said Katie Cabrera, CEO of Happy Breathing. "Our goal is to provide parents with a safe and effective solution that they can use in the comfort of their own home, reducing the need for stressful hospital visits."

The Happy Breathing baby nasal aspirator is suitable for infants from birth to 6 years of age, offering relief for a wide range of respiratory conditions, including RSV, bronchitis, and the common flu. The device has been tested to ensure that it meets the highest safety and efficacy standards, giving parents the confidence to use it on their precious little ones.

Users can visit the official website https://www.happybreathingsuction.com/ for any media or commercial inquiries.

Follow Happy Breathing on Social Media:

Instagram: https://www.instagram.com/happybreathing_/

LinkedIn: https://www.linkedin.com/company/happy-breathing

Facebook: https://www.facebook.com/profile.php?id=61557083368318

About Company:

Happy Breathing is a pioneering company in pediatric healthcare dedicated to providing innovative solutions for parents caring for infants. Founded by Katie Cabrera, a Neonatal Respiratory Therapist, Happy Breathing aims to make infant respiratory care more accessible and convenient for parents.

Media Contact
Company Name: Happy Breathing
Contact Person: Katie Cabrera
Email:Send Email
City: Riverside
State: CA
Country: United States
Website: www.happybreathingsuction.com

Thursday, April 25, 2024

Celiac Disease Pipeline Analysis 2024: Clinical Trials, FDA Approvals, Emerging Therapies, ROA, MOA and Treatment Outlook by DelveInsight | Amgen, AMYRA Biotec, Equillium Bio, Chugai Pharmaceutical

Celiac Disease Pipeline

As per DelveInsight's assessment, globally, Celiac Disease pipeline constitutes 25+ key companies continuously working towards developing 25+ Celiac Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

(New York, United States) “Celiac Disease Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Celiac Disease Market.

The Celiac Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Request for Sample Report @ Celiac Disease Pipeline Outlook

Some of the key takeaways from the Celiac Disease Pipeline Report:

Celiac Disease Companies across the globe are diligently working toward developing novel Celiac Disease treatment therapies with a considerable amount of success over the years.
Celiac Disease companies working in the treatment market are 9Metres Biopharma, Amgen, Allero Therapeutics, Takeda, Calypso Biotech, Anokion, Zedira GmbH, Millennium Pharmaceuticals, ImmunogenX, GlaxoSmithKline, ImmusanT, ActoBio Therapeutics, Amyra biotech, and others, are developing therapies for the Celiac Disease treatment

Emerging Celiac Disease therapies in the different phases of clinical trials are- AMY02, EQ102, DONQ52, CALY-002, Latiglutenase, Ordesekimab, and others are expected to have a significant impact on the Celiac Disease market in the coming years.
On March 2024, Takeda announced results of a Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of TAK-062 for the Treatment of Active Celiac Disease in Subjects Attempting a Gluten-Free Diet
On March 2024, Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA announced results of a Phase 2a Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of KAN-101 In Participants With Celiac Disease.
On December 2023, Topas Therapeutics GmbH announced results of a Double-blind, Randomized, Placebo-controlled, Phase 2a Study to Evaluate the Safety, Tolerability, and Pharmacodynamic (PD) Effects of Two Infusions of Escalating Doses of TPM502 in Adults Diagnosed With Celiac Disease.
On November 2023, Chugai Pharmaceutical announced results of a Phase I, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate The Safety, Tolerability, Pharmacokinetics, and Biomarkers of DONQ52 in Celiac Disease Patients (LILY Study).
On September 2023, Regeneron Pharmaceuticals announced results of a study based on T Cell Receptor (TCR) Sequencing and Transcriptional Profiling in Adult Celiac Disease Patients Undergoing Gluten Challenge.

Celiac Disease Overview

Celiac disease is an autoimmune disorder triggered by the ingestion of gluten—a protein found in wheat, barley, and rye—in genetically predisposed individuals. When someone with celiac disease consumes gluten, their immune system responds by damaging the lining of the small intestine. This damage impairs the absorption of nutrients from food, leading to various symptoms and potential long-term complications.

Symptoms of celiac disease can vary widely and may include gastrointestinal issues like diarrhea, abdominal pain, bloating, and constipation, as well as non-gastrointestinal symptoms such as fatigue, joint pain, skin rashes, and neurological problems.

Diagnosis typically involves blood tests to check for specific antibodies associated with celiac disease, followed by confirmation through a biopsy of the small intestine to assess for characteristic damage to the intestinal lining.

The primary treatment for celiac disease is strict adherence to a gluten-free diet, which involves avoiding all foods containing wheat, barley, and rye. This typically leads to symptom resolution, intestinal healing, and prevention of complications. Additionally, individuals with celiac disease may benefit from nutritional supplementation and regular monitoring by healthcare professionals to ensure optimal management of the condition and prevent potential deficiencies or complications.

Get a Free Sample PDF Report to know more about Celiac Disease Pipeline Therapeutic Assessment- https://www.delveinsight.com/sample-request/celiac-disease-pipeline-insight

Emerging Celiac Disease Drugs Under Different Phases of Clinical Development Include:

AMY02 : AMYRA Biotech AG
EQ102 : Equillium Bio.
DONQ52 : Chugai Pharmaceutical Co., Ltd.
CALY-002 : Calypso Biotech
Latiglutenase : ImmunogenX, Inc.
Ordesekimab : Amgen Inc.

Celiac Disease Route of Administration

Celiac Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

Intra-articular
Intraocular
Intrathecal
Intravenous
Ophthalmic
Oral
Parenteral
Subcutaneous
Topical
Transdermal
Molecule Type

Celiac Disease Molecule Type

Celiac Disease Products have been categorized under various Molecule types, such as

Oligonucleotide
Peptide
Small molecule

Celiac Disease Pipeline Therapeutics Assessment

Celiac Disease Assessment by Product Type
Celiac Disease By Stage and Product Type
Celiac Disease Assessment by Route of Administration
Celiac Disease By Stage and Route of Administration
Celiac Disease Assessment by Molecule Type
Celiac Disease by Stage and Molecule Type

DelveInsight’s Celiac Disease Report covers around 25+ products under different phases of clinical development like

Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration

Further Celiac Disease product details are provided in the report. Download the Celiac Disease pipeline report to learn more about the emerging Celiac Disease therapies- https://www.delveinsight.com/sample-request/celiac-disease-pipeline-insight

Some of the key companies in the Celiac Disease Therapeutics Market include:

Key companies developing therapies for Celiac Disease are – 9 Metres Biopharma, Amgen, Allero Therapeutics, Takeda, Calypso Biotech, Anokion, Zedira GmbH, Millennium Pharmaceuticals, ImmunogenX, GlaxoSmithKline, ImmusanT, ActoBio Therapeutics, Amyra biotech, and others.

Celiac Disease Pipeline Analysis:

The Celiac Disease pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Celiac Disease with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Celiac Disease Treatment.
Celiac Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Celiac Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Celiac Disease market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Celiac Disease drugs and therapies - https://www.delveinsight.com/sample-request/celiac-disease-pipeline-insight

Celiac Disease Pipeline Market Drivers

Increasing prevalence of Celiac Disease, increasing R&D activities, no Approved Therapy are some of the important factors that are fueling the Celiac Disease Market.

Celiac Disease Pipeline Market Barriers

However, limited patient awareness about the disease, poor Patient Compliance and other factors are creating obstacles in the Celiac Disease Market growth.

Scope of Celiac Disease Pipeline Drug Insight

Coverage: Global
Key Celiac Disease Companies: 9Metres Biopharma, Amgen, Allero Therapeutics, Takeda, Calypso Biotech, Anokion, Zedira GmbH, Millennium Pharmaceuticals, ImmunogenX, GlaxoSmithKline, ImmusanT, ActoBio Therapeutics, Amyra biotech, and others
Key Celiac Disease Therapies: AMY02, EQ102, DONQ52, CALY-002, Latiglutenase, Ordesekimab, and others
Celiac Disease Therapeutic Assessment: Celiac Disease current marketed and Celiac Disease emerging therapies
Celiac Disease Market Dynamics: Celiac Disease market drivers and Celiac Disease market barriers

Request for Sample PDF Report for Celiac Disease Pipeline Assessment and clinical trials - https://www.delveinsight.com/sample-request/celiac-disease-pipeline-insight

Table of Contents

1. Celiac Disease Report Introduction

2. Celiac Disease Executive Summary

3. Celiac Disease Overview

4. Celiac Disease- Analytical Perspective In-depth Commercial Assessment

5. Celiac Disease Pipeline Therapeutics

6. Celiac Disease Late Stage Products (Phase II/III)

7. Celiac Disease Mid Stage Products (Phase II)

8. Celiac Disease Early Stage Products (Phase I)

9. Celiac Disease Preclinical Stage Products

10. Celiac Disease Therapeutics Assessment

11. Celiac Disease Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Celiac Disease Key Companies

14. Celiac Disease Key Products

15. Celiac Disease Unmet Needs

16 . Celiac Disease Market Drivers and Barriers

17. Celiac Disease Future Perspectives and Conclusion

18. Celiac Disease Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Ankit Nigam
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432, Las Vegas NV 89107
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services

Diabetic Kidney Disease Market is anticipated to Grow at a CAGR of ~6.5% by 2034, analyzes DelveInsight | Boehringer Ingelheim, Daiichi Sankyo, ProKidney, Chinook Therapeutics, AbbVie,Inversago Pharma

Diabetic Kidney Disease Market

The dynamics of the diabetic kidney disease market are anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, rising awareness of the disease, incremental healthcare spending worldwide, and the expected launch of emerging therapies

(Albany, USA) DelveInsight's Diabetic Kidney Disease Market Insights report includes a comprehensive understanding of current treatment practices, diabetic kidney disease emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

Key Takeaways from the Diabetic Kidney Disease Market Report

According to DelveInsight's analysis, the market size for diabetic kidney disease reached USD 7.2 billion in 2023 across the 7MM and is expected to grow with a significant CAGR by 2034.
DelveInsight's analysis reveals that the overall prevalent population of diabetic kidney disease in the 7MM was reported as ~33 million in 2023.
Leading diabetic kidney disease companies such as Boehringer Ingelheim, Daiichi Sankyo, ProKidney, Chinook Therapeutics (a Novartis company), AbbVie, Inversago Pharma (a Novo Nordisk Company), Mineralys Therapeutics, CSL Behring, Teijin Pharma, Dimerix, Chugai Pharmaceutical, Lisata Therapeutics and others are developing novel diabetic kidney disease drugs that can be available in the diabetic kidney disease market in the coming years.
The promising diabetic kidney disease therapies in the pipeline include Esaxerenone (CS-3150), REACT (Renal Autologous Cell Therapy), Zibotentan + dapagliflozin, BI 690517 ± empagliflozin, Atrasentan, Tozorakimab (MEDI3506) + dapagliflozin, INV-202, and others.

Discover which therapies are expected to grab the major diabetic kidney disease market share @ Diabetic Kidney Disease Market Report

Diabetic Kidney Disease Overview

Diabetic kidney disease (DKD), also referred to as diabetic nephropathy (DN), is a clinical condition marked by persistent albuminuria and a gradual decline in renal function. This term implies the existence of a recognizable pattern of glomerular disease. Typically, Diabetic Kidney Disease is linked with high blood pressure, leading to increased cardiovascular risks and mortality. The causes of DKD are intricate and likely involve various factors, with hyperglycemia being the primary contributor. Initial stages of Diabetic Kidney Disease may be asymptomatic, but as renal function diminishes, the accumulation of toxic wastes can lead to symptoms such as nausea, vomiting, loss of appetite, hiccups, and weight gain due to fluid retention. Untreated cases may progress to heart failure and pulmonary edema.

Detecting and diagnosing Diabetic Kidney Disease poses challenges. Screening and renal biopsy are the main diagnostic methods used to identify Diabetic Kidney Disease in patients. In instances of nonalbuminuric DKD, other potential diagnoses considered include ischemic nephropathy, dysproteinemia, and tubulointerstitial nephritis (TIN).

Diabetic Kidney Disease Epidemiology Segmentation

Among the 7MM, the United States accounted for the highest number of diagnosed prevalent cases of DKD, i.e., ~45% of the total cases in the 7MM in 2023.

Among EU4 and the UK, Germany accounted for the largest number of DKD cases, whereas France accounted for the lowest number of cases in 2023.

The diabetic kidney disease market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

Total Prevalent Cases of Diabetes
Total Prevalent Cases of Diabetic Kidney Disease
Total Diagnosed Prevalent Cases of Diabetic Kidney Disease
Age-specific Cases of Diabetic Kidney Disease
Stage-specific Cases of Diabetic Kidney Disease

Request for Sample Report @ https://www.delveinsight.com/sample-request/diabetic-kidney-disease-dkd-market

Diabetic Kidney Disease Treatment Market

The primary approach to treating DKD involves the reduction of blood pressure, as even a slight elevation in blood pressure can rapidly exacerbate kidney disease. Additionally, it is crucial to manage blood sugar levels to decelerate the progression of diabetic nephropathy. Fundamental methods for lowering blood pressure encompass weight loss, reduced salt intake, abstaining from alcohol and tobacco, and engaging in regular exercise.

The preferred medications for blood pressure management often include angiotensin-converting enzyme (ACE) inhibitors. Capoten (captopril), unlike many ACE inhibitors, is not a prodrug. It competes with AT-I for ACE binding, hindering the enzymatic breakdown of angiotensin I (AT-I) into angiotensin II (AT-II), consequently heightening plasma renin activity. Another medication, enalapril, is an inactive prodrug that undergoes hepatic transformation to generate enalaprilat, its active form. Enalaprilat acts on the Renin-Angiotensin-Aldosterone System (RAAS) to impede ACE, leading to the suppression of RAAS and exhibiting antihypertensive effects in individuals with low-renin hypertension.

In September 2019, the US Food and Drug Administration (FDA) approved the first therapeutic drug designed to treat DKD, INVOKANA (canagliflozin). This medication, categorized as a sodium-glucose co-transporter 2 (SGLT2) inhibitor, plays a crucial role in the majority of glucose reabsorption from the tubular lumen. Canagliflozin inhibits SGLT2, resulting in a decrease in the reabsorption of filtered glucose, a reduction in the renal threshold for glucose (RTG), and consequently, an increase in urinary glucose excretion (UGE). Furthermore, in August 2019, the European Medicines Agency (EMA) accepted the submission for the extension of its license.

To know more about diabetic kidney disease treatment guidelines, visit @ Diabetic Kidney Disease Market Report

Diabetic Kidney Disease Pipeline Therapies and Key Companies

MINNEBRO (ESAXERENONE/CS-3150): DAIICHI SANKYO
REACT (RENAL AUTOLOGOUS CELL THERAPY): PROKIDNEY
ZIBOTENTAN + DAPAGLIFLOZIN: ASTRAZENECA
VYLEESI (BREMELANOTIDE): PALATIN
TOZORAKIMAB (MEDI3506) + DAPAGLIFLOZIN: ASTRAZENECA
ATRASENTAN: CHINOOK THERAPEUTICS/NOVARTIS
LORUNDROSTAT: MINERALYS THERAPEUTICS
BI 690517 + EMPAGLIFLOZIN: BOEHRINGER INGELHEIM
INV-202: INVERSAGO PHARMA

Learn more about the FDA-approved drugs for diabetic kidney disease @ https://www.delveinsight.com/sample-request/diabetic-kidney-disease-dkd-market

Diabetic Kidney Disease Market Dynamics

The dynamics of the DKD market are expected to change in the coming years. The global rise in diabetes prevalence has contributed significantly to the surge in DKD cases, creating a substantial patient population in need of effective treatments. As awareness about the complications associated with diabetes, including kidney disease, increases, there is a growing demand for therapeutic interventions that specifically target DKD. Additionally, advancements in diagnostic technologies enable earlier and more accurate detection of kidney disease in diabetic patients, fostering a proactive approach to management.

Furthermore, many potential therapies are being investigated for the treatment of DKD, and it is safe to predict that the treatment space will significantly impact the DKD market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the diabetic kidney disease market in the 7MM.

However several factors may impede the growth of the DKD market. One of the primary challenges is the complexity of the disease itself. DKD is intricately linked to diabetes, a condition with multifaceted causes and manifestations. This complexity makes it challenging to develop targeted and effective treatments.

Moreover, DKD treatment poses a significant economic burden and disrupts patients' overall well-being and QOL. Furthermore, the DKD market growth may be offset by failures and discontinuation of emerging therapies. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the Diabetic Kidney Disease market growth.

A deeper understanding of the molecular mechanisms of DKD onset and progression is necessary for the development of new and innovative treatments for DKD. Furthermore, as DKD often goes undiagnosed due to its initial lack of symptoms, the use of advanced predictive tests for early detection can augment physicians' capacity to make well-informed treatment decisions. This, in turn, can result in improved clinical outcomes and streamline more effective therapeutic interventions.

Scope of the Diabetic Kidney Disease Market Report

Study Period: 2020–2034
Coverage: 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Diabetic Kidney Disease Market CAGR (2020–2034): 6.5 %
Diabetic Kidney Disease Market Size in 2023: USD 7.2 Billion
Key Diabetic Kidney Disease Companies: Johnson & Johnson, Mitsubishi Tanabe Pharma, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Daiichi Sankyo, ProKidney, Chinook Therapeutics (a Novartis company), AbbVie, Inversago Pharma (a Novo Nordisk Company), Mineralys Therapeutics, CSL Behring, Teijin Pharma, Dimerix, Chugai Pharmaceutical, Lisata Therapeutics and others
Key Pipeline Diabetic Kidney Disease Therapies: MINNEBRO (ESAXERENONE/CS-3150), REACT (RENAL AUTOLOGOUS CELL THERAPY), ZIBOTENTAN + DAPAGLIFLOZIN, VYLEESI (BREMELANOTIDE), TOZORAKIMAB (MEDI3506) + DAPAGLIFLOZIN, ATRASENTAN, LORUNDROSTAT, BI 690517 + EMPAGLIFLOZIN, INV-202, and others
Therapeutic Assessment: Diabetic Kidney Disease current marketed and emerging therapies
Diabetic Kidney Disease Market Dynamics: Key Market Forecast Assumptions of Emerging Diabetic Kidney Disease Drugs, Conjoint Analysis and Market Outlook
Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
Unmet Needs, KOL's views, Analyst's views, Diabetic Kidney Disease Market Access and Reimbursement

Discover more about diabetic kidney disease drugs in development @ https://www.delveinsight.com/sample-request/diabetic-kidney-disease-dkd-market

Table of Contents

1. Diabetic Kidney Disease Key Insights

2. Diabetic Kidney Disease Report Introduction

3. Diabetic Kidney Disease Overview at a Glance

4. Diabetic Kidney Disease Executive Summary

5. Diabetic Kidney Disease Key Events

6. Epidemiology and Market Forecast Methodology

7. Disease Background and Overview

8. Diabetic Kidney Disease Treatment and Management

9. Diabetic Kidney Disease Guidelines

10. Diabetic Kidney Disease Epidemiology and Patient Population

11. Patient Journey

12. Key Endpoints in Diabetic Kidney Disease

13. Diabetic Kidney Disease Marketed Drugs

14. Diabetic Kidney Disease Emerging Drugs

15. 7MM Diabetic Kidney Disease Market Analysis

16. Market Access and Reimbursement

17. KOL Views

18. Unmet Needs

19. SWOT Analysis

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Rheumatoid Arthritis Pipeline Assessment 2024: Clinical Trials, FDA, EMA, and PMDA Approvals, Therapies, Treatment Market, Growth Prospects, and Companies by DelveInsight

Rheumatoid Arthritis pipeline

Rheumatoid Arthritis pipeline report including 120+ key companies and 120+ Rheumatoid Arthritis treatment therapies, analyses DelveInsight

(Albany, USA) “Rheumatoid Arthritis Pipeline Insight 2024” report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Rheumatoid Arthritis Market.

The Rheumatoid Arthritis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

To know more about the Rheumatoid Arthritis Pipeline Analysis, click here: Rheumatoid Arthritis Pipeline Insight

Some of the key takeaways from the Rheumatoid Arthritis Pipeline Report:

Rheumatoid Arthritis Companies across the globe are diligently working toward developing novel Rheumatoid Arthritis treatment therapies with a considerable amount of success over the years.
Rheumatoid Arthritis companies working in the treatment market are Taisho Pharmaceutical, Zhejiang Hisun Pharmaceutical, SinoMab, Jiangsu Hengrui Medicine, RemeGen, GlaxoSmithKline, Modern Biosciences, Jiangsu Alphamab Biopharmaceuticals, Akros Pharma, Hanlim Pharm, Galapagos NV, Chong Kun Dang Pharmaceutical, Bristol Myers Squibb, AstraZeneca, Aclaris Therapeutics, Abivax, AbbVie, Synact Pharma, Gilead sciences, Mesoblast, Rottapharm Biotech, Eli Lilly and Company, Kiniksa Pharmaceuticals, Abcentra, Cyxone, Yungjin Pharm. Co., Ltd. Taiho Pharmaceutical, Oscotec Inc., Pfizer, Janssen Research & Development, Cipher Pharmaceuticals Inc., KLUS Pharma Inc., Revolo Biotherapeutics, Lynk Pharmaceuticals, Beijing Baylx Biotech, Hope Biosciences, Kangstem Biotech, Celltex Therapeutics, I-Mab Biopharma Co. Ltd., Synermore Biologics Co., Ltd, Oryn Therapeutics, Arthrogen, Bayer, Amgen, Draconis Pharma, Biozeus, Landos Biopharma, Imcyse, Kymera Therapeutics, RedHill Biopharma, 4D Pharma, CV6 Therapeutics, VYNE Therapeutics, MyMD Pharmaceuticals, Brickell Biotech Inc, Worg Pharmaceuticals, Almirall, Standigm, Metrion Biosciences, Jnana Therapeutics, Silo Pharma, SFA Therapeutics, Neutrolis Therapeutics, Ahead Therapeutics, Fresenius Kabi, Kidswell Bio, BioXpress Therapeutics, CinnaGen, Alvotech, Hetero Biopharma, Shanghai Henlius Biotech, Cadila Pharmaceuticals, Innovent Biologics, Torrent Pharmaceuticals, Emcure Pharmaceuticals, mAbxience, Shanghai Junshi Biosciences, Enosi Therapeutics, and others, are developing therapies for the Rheumatoid Arthritis treatment.
Emerging Rheumatoid Arthritis therapies such as TS152, HS-016, SM03, SHR0302, RC18, Otilimab, NI-0101, MBS2320, KN019, JTE-051, Interleukin 2, HL237, GLPG3970, Elsubrutinib, CKD-506, Branebrutinib, AZD9567, ATI-450, ABX464, ABBV 3373, ABBV 154, AP1189, F8IL10, AMT-101, GS-9876, CR 6086, LY 3462817, KPL-404, Orticumab, Rabeximod, YRA 1909, VIB4920, Varicella Zoster Vaccine, TAS5315, SKI-O-703, SAN-300, PF-06650833, Nipocalimab, CF-101, A223, IRL 201805, LNK 01001, PRTX-100, hUC-MSC infusion, HB-adMSC, LABP-104, VAY736, TJ003234 , SYN060, GS-5718, PF-06835375, Nivolumab, MH004, ORTD-1, ART-I02, FB704A, Amilo 5MER, CKD-374 , CFZ-533, BAY 1830839, AMG 570, JNJ-4703, CT-P47, BZ068, Invossa, LABP-69, ICM-203-R, NX-5948, KT-474 , Clarithromycin/clofazimine/rifabutin (RHB-104), Research programme: small molecule TYK2 inhibitors, MRx0006, CV6 1271, VYN201, MYMD-1, BBI 02, Research Programme: Immune mediated diseases, Foralumab, SPU-21, SFA002, NTR-441, Research programme: autoimmune disease therapeutics, AT_1001, MSB11456, MabionCD20, DMB-3113, GB232, GBS 005, TX17, BX 2922, Cinnora, AVT02, MYL-1401A, and others are expected to have a significant impact on the Rheumatoid Arthritis market in the coming years.
On January 2024, Rise Therapeutics LLC announced results of a Single and Repeat Dosing Study of the Safety, Drug Exposure and Clinical Activity of R-2487 in Patients with Rheumatoid Arthritis.
On March 2024, Sonoma Biotherapeutics, Inc announced results of a Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Activity of Single Ascending Doses of SBT777101 in Subjects with Rheumatoid Arthritis.
On March 2024, Lynk Pharmaceuticals Co., Ltd announced results of a Randomized, Double-blind Study to Compare LNK01001 to Placebo in Adults with Rheumatoid Arthritis (RA) on a Stable Dose of csDMARDs Who Have an Inadequate Response or Intolerance to bDMARDs.
On February 2024, Eli Lilly and Company announced results of an Adaptive Phase 2a/2b, Randomized, Double-Blind, Placebo-Controlled Study of LY3871801 in Adult Participants With Moderately-to-Severely Active Rheumatoid Arthritis.
On April 2024, AbbVie announced results of a Phase 3b/4 Randomized, Double-Blind, Double Dummy, Active Comparator-Controlled Study, Comparing the Efficacy and Safety of Upadacitinib Versus Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis on a Stable Background of MTX and Who Had an Inadequate Response or Intolerance to a Single TNF Inhibitor (SELECT- SWITCH).
On March 2024, AstraZeneca announced results of a Phase I, Randomised, Double-blind, Placebo-controlled, Single Ascending Dose Study of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of Subcutaneous AZD6912 in Healthy Participants.

Rheumatoid Arthritis Overview:

Rheumatoid arthritis (RA) is a chronic autoimmune disorder that primarily affects the joints, causing inflammation, pain, stiffness, and potential joint damage and deformity over time. It occurs when the immune system mistakenly attacks the body's own tissues, particularly the synovium—the lining of the membranes that surround the joints. Rheumatoid arthritis commonly affects smaller joints like those in the hands and feet, but it can also impact larger joints and other organs. Rheumatoid arthritis Symptoms often fluctuate in severity and can include fatigue, joint swelling, and reduced range of motion. Early Rheumatoid arthritis diagnosis and aggressive treatment are vital in managing Rheumatoid arthritis to slow disease progression, alleviate symptoms, and preserve joint function. Rheumatoid arthritis Treatment typically involves a combination of medications (such as disease-modifying anti-rheumatic drugs and biologics), physical therapy, lifestyle modifications, and sometimes surgery to repair or replace severely damaged joints.

DelveInsight’s Rheumatoid Arthritis Report covers around 120+ products under different phases of clinical development like

Late-stage Rheumatoid Arthritis products (Phase III)
Mid-stage Rheumatoid Arthritis products (Phase II)
Early-stage Rheumatoid Arthritis product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Rheumatoid Arthritis Route of Administration

Request for free sample Report here @ https://www.delveinsight.com/sample-request/rheumatoid-arthritis-ra-pipeline-insight

Emerging Rheumatoid Arthritis Drugs Under Different Phases of Clinical Development Include:

TS152: Taisho Pharmaceutical
SM03: SinoMab
SHR0302: Jiangsu Hengrui Medicine
RC18: RemeGen
Otilimab: GlaxoSmithKline
ATI-450: Aclaris Therapeutics
MBS2320: Modern Biosciences
PF-06651600: Pfizer
Obefazimod: Abivax
ABBV-154: AbbVie
Branebrutinib: Bristol Myers Squibb
KPL-404: Kiniksa Pharmaceuticals
ORTD-1: Oryn Therapeutics
MRx0006: 4D pharma plc.
LABP-69: Landos Biopharma, Inc
BZ068: Biozeus
And Many Others.

Further Rheumatoid Arthritis product details are provided in the report. Download the Rheumatoid Arthritis report to learn more about the emerging Rheumatoid Arthritis therapies @ https://www.delveinsight.com/sample-request/rheumatoid-arthritis-ra-pipeline-insight

Rheumatoid Arthritis Pipeline Analysis

The Rheumatoid Arthritis pipeline report provides insights into:

The report provides detailed insights about companies that are developing therapies for the treatment of Rheumatoid Arthritis with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for the Rheumatoid Arthritis Treatment.
Rheumatoid Arthritis key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Rheumatoid Arthritis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Rheumatoid Arthritis market.

The Rheumatoid Arthritis therapeutics report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Rheumatoid Arthritis therapies and drugs @ https://www.delveinsight.com/sample-request/rheumatoid-arthritis-ra-pipeline-insight

Key companies in the Rheumatoid Arthritis Therapeutics Market:

Some of the Rheumatoid Arthritis Companies working in the market are Taisho Pharmaceutical, Zhejiang Hisun Pharmaceutical, SinoMab, Jiangsu Hengrui Medicine, RemeGen, GlaxoSmithKline, Modern Biosciences, Jiangsu Alphamab Biopharmaceuticals, Akros Pharma, Hanlim Pharm, Galapagos NV, Chong Kun Dang Pharmaceutical, Bristol Myers Squibb, AstraZeneca, Aclaris Therapeutics, Abivax, AbbVie, Synact Pharma, Gilead sciences, Mesoblast, Rottapharm Biotech, Eli Lilly and Company, Kiniksa Pharmaceuticals, Abcentra, Cyxone, Yungjin Pharm. Co., Ltd. Taiho Pharmaceutical, Oscotec Inc., Pfizer, Janssen Research & Development, Cipher Pharmaceuticals Inc., KLUS Pharma Inc., Revolo Biotherapeutics, Lynk Pharmaceuticals, Beijing Baylx Biotech, Hope Biosciences, Kangstem Biotech, Celltex Therapeutics, I-Mab Biopharma Co. Ltd., Synermore Biologics Co., Ltd, Oryn Therapeutics, Arthrogen, Bayer, Amgen, Draconis Pharma, Biozeus, Landos Biopharma, Imcyse, Kymera Therapeutics, RedHill Biopharma, 4D Pharma, CV6 Therapeutics, VYNE Therapeutics, MyMD Pharmaceuticals, Brickell Biotech Inc, Worg Pharmaceuticals, Almirall, Standigm, Metrion Biosciences, Jnana Therapeutics, Silo Pharma, SFA Therapeutics, Neutrolis Therapeutics, Ahead Therapeutics, Fresenius Kabi, Kidswell Bio, BioXpress Therapeutics, CinnaGen, Alvotech, Hetero Biopharma, Shanghai Henlius Biotech, Cadila Pharmaceuticals, Innovent Biologics, Torrent Pharmaceuticals, Emcure Pharmaceuticals, mAbxience, Shanghai Junshi Biosciences, Enosi Therapeutics, and others.

Request for Sample PDF Report to know in detail about Rheumatoid Arthritis clinical trial advancements @ https://www.delveinsight.com/sample-request/rheumatoid-arthritis-ra-pipeline-insight

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Rheumatoid Arthritis Current Treatment Patterns

4. Rheumatoid Arthritis – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Rheumatoid Arthritis Late Stage Products (Phase-III)

7. Rheumatoid Arthritis Mid-Stage Products (Phase-II)

8. Rheumatoid Arthritis Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Rheumatoid Arthritis Products

11. Dormant Rheumatoid Arthritis Products

12. Rheumatoid Arthritis Discontinued Products

13. Rheumatoid Arthritis Product Profiles

14. Key Companies in the Rheumatoid Arthritis Market

15. Key Products in the Rheumatoid Arthritis Therapeutics Segment

16. Dormant and Discontinued Products

17. Rheumatoid Arthritis Unmet Needs

18. Rheumatoid Arthritis Future Perspectives

19. Rheumatoid Arthritis Analyst Review

20. Appendix

21. Report Methodology

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email:Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services

Peripheral T-cell Lymphoma Market Forecast 2032: Clinical Trials, Epidemiology Trends, FDA Approvals, Companies & Growth Analysis Report by DelveInsight

Peripheral T-cell Lymphoma Market

Peripheral T-cell Lymphoma companies are Eisai, Celgene Corporation, HUYA Bioscience International/Quintiles, Verastem, BeiGene, Merck Sharp & Dohme Corp, Solasia Pharma, Aileron Therapeutics, Incyte, Novartis, and others.

(Albany, USA) DelveInsight's "Peripheral T-cell Lymphoma Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Peripheral T-cell Lymphoma, historical and forecasted epidemiology as well as the Peripheral T-cell Lymphoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Peripheral T-cell Lymphoma market report offers information on current treatment methods, new drugs, the market share of different therapies, and the present and projected size of the Peripheral T-cell Lymphoma market from 2019 to 2032. The report is divided into segments covering seven major markets. Additionally, it includes details about the current treatment practices and algorithms for Peripheral T-cell Lymphoma, factors driving the market, obstacles faced, and areas with unmet medical needs. This comprehensive report aims to identify the best opportunities and evaluate the potential of the Peripheral T-cell Lymphoma market.

Request for a Free Sample Report @ Peripheral T-cell Lymphoma Market Forecast

Some facts of the Peripheral T-cell Lymphoma Market Report are:

Peripheral T-cell Lymphoma market size in the United States is expected to increase with a CAGR of 4.9% during the study period (2019-2032).
Leading Peripheral T-cell Lymphoma companies working in the market are Eisai, Celgene Corporation, HUYA Bioscience International/Quintiles, Verastem, BeiGene, Merck Sharp & Dohme Corp, Solasia Pharma, Aileron Therapeutics, Incyte, Novartis, and others.
Key Peripheral T-cell Lymphoma Therapies expected to launch in the market are Beleodaq (Belinostat, Acrotech Biopharma); Istodax (Romidepsin), Folotyn (Pralatrexate, Acrotech Biopharma), Arranon (Nelarabine, GlaxoSmithKline), and Adcetris (Brentuximab vedotin, Seattle Genetics), and others.
The total incident population of Peripheral T-cell Lymphoma in the 7MM comprised of 18,027 cases in 2021 and are projected to increase during the forecast period.
On April 2024, Affimed GmbH announced results of a Phase 2, Open-Label, Multi-Center Study of Innate Cell Engager AFM13 in Combination With Allogeneic Natural Killer Cells (AB-101) in Subjects With Recurrent or Refractory Hodgkin Lymphoma and CD-30 Positive Peripheral T-Cell Lymphoma.
On April 2024, Astex Pharmaceuticals announced results of a Phase 1-2, Open-Label Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Activity of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Subjects With Relapsed/Refractory Peripheral T-cell Lymphoma.
On February 2024, Acrotech Biopharma Inc announced results of a Phase 3, Randomized, Open-Label Study Comparing the Efficacy and Safety of the Combination of Beleodaq-CHOP or Folotyn-COP to the CHOP Regimen Alone in Newly Diagnosed Patients With Peripheral T-Cell Lymphoma.
On February 2024, Seagen Inc announced results of a Dual-cohort, Open-label, Phase 2 Study of Brentuximab Vedotin and CHP (A+CHP) in the Frontline Treatment of Subjects With Peripheral T-cell Lymphoma (PTCL) With Less Than 10% CD30 Expression.
On January 2024, Sichuan Baili Pharmaceutical Co., Ltd announced results of an Open, Multicenter, Phase Ib/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics/Pharmacokinetics, and Antitumor Activity of GNC-038 Injection in Relapsed or Refractory NK/ T-cell Lymphoma, AITL, and Other NHL.

Peripheral T-cell Lymphoma Overview

Peripheral T-cell lymphomas (PTCLs) are an uncommon and heterogeneous group of clinically aggressive types of non-Hodgkin lymphoma (NHL) that develop in mature white blood cells called "T cells" and "natural killer (NK) cells." It is PTCL's origin in the lymphatic system that gave it the name peripheral T-cell lymphoma. In the case of PTCL, the term "peripheral" does not refer to the extremities, but identifies PTCL as cancer that arises in the lymphoid tissues outside of the bone marrow such as lymph nodes, spleen, gastrointestinal tract, and skin.

Learn more about Peripheral T-cell Lymphoma treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ https://www.delveinsight.com/sample-request/peripheral-t-cell-lymphoma-ptcl-market

Peripheral T-cell Lymphoma Market

The Peripheral T-cell Lymphoma market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Peripheral T-cell Lymphoma market trends by analyzing the impact of current Peripheral T-cell Lymphoma therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Peripheral T-cell Lymphoma market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Peripheral T-cell Lymphoma market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Peripheral T-cell Lymphoma market in 7MM is expected to witness a major change in the study period 2019-2032.

Peripheral T-cell Lymphoma Epidemiology

The Peripheral T-cell Lymphoma epidemiology section provides insights into the historical and current Peripheral T-cell Lymphoma patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Peripheral T-cell Lymphoma market report also provides the diagnosed patient pool, trends, and assumptions.

Peripheral T-cell Lymphoma Epidemiology Segmentation in the 7MM

Total Peripheral T-cell Lymphoma Incident Cases
Peripheral T-cell Lymphoma Stage-Specific Incident Cases (Stage I, Stage II, Stage III, and Stage IV)
Peripheral T-cell Lymphoma Subtype-Specific Incident Cases (PTCL-NOS, ALCL, AITL, nasal NK/T-cell lymphoma, enteropathy-type intestinal TCL, hepatosplenic TCL, and others)

Explore more about Peripheral T-cell Lymphoma Epidemiology @ https://www.delveinsight.com/sample-request/peripheral-t-cell-lymphoma-ptcl-market

Peripheral T-cell Lymphoma Drugs Uptake

This section focuses on the uptake rate of the potential Peripheral T-cell Lymphoma drugs recently launched in the Peripheral T-cell Lymphoma market or expected to be launched in 2019-2032. The analysis covers the Peripheral T-cell Lymphoma market uptake by drugs, patient uptake by therapies, and sales of each drug.

Peripheral T-cell Lymphoma Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Peripheral T-cell Lymphoma market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Peripheral T-cell Lymphoma Companies and Pipeline Therapies

Denileukin diftitox: Eisai
SP-02 (Darinaparsin, ZIO-101): Solasia Pharma
Fenretinide (4-HPR): CerRx
Tipifarnib: Kura Oncology
HBI-8000: HUYA Bioscience International/Quintiles, Inc.
COPIKTRA (Duvelisib): Verastem
Genolimzumab (GB226): Genor Biopharma
Azacitidine (CC-486): Celgene Corporation
Tislelizumab: BeiGene
Lacutamab/IPH4102: Innate Pharma
AFM13: Affimed GmbH
Opdivo (nivolumab) + Cabiralizumab: Bristol-Myers Squibb
Bavencio (avelumab): Pfizer
Keytruda (pembrolizumab): Merck Sharp & Dohme Corp.
STI-3031/IMC-001: Sorrento Therapeutics
ALRN 6924: Aileron Therapeutics
Masitinib: AB Science
Ruxolitinib: Incyte Corporation/Novartis
Aplidin (plitidepsin): PharmaMar
ASTX660: Otsuka Pharmaceutical/Astex Pharmaceuticals

Request for a sample report to understand more about the Peripheral T-cell Lymphoma pipeline development activities @ https://www.delveinsight.com/sample-request/peripheral-t-cell-lymphoma-ptcl-market

Peripheral T-cell Lymphoma Therapeutics Assessment

Leading companies are actively engaged in the Peripheral T-cell Lymphoma Therapeutics sector, focusing on creating innovative treatments that will significantly impact the future of Peripheral T-cell Lymphoma treatment. Peripheral T-cell Lymphoma companies include Eisai, Celgene Corporation, HUYA Bioscience International/Quintiles, Verastem, BeiGene, Merck Sharp & Dohme Corp, Solasia Pharma, Aileron Therapeutics, Incyte, Novartis, and various others.

Learn more about the emerging Peripheral T-cell Lymphoma therapies & key companies @ https://www.delveinsight.com/sample-request/peripheral-t-cell-lymphoma-ptcl-market

Peripheral T-cell Lymphoma Report Key Insights

1. Peripheral T-cell Lymphoma Patient Population

2. Peripheral T-cell Lymphoma Market Size and Trends

3. Key Cross Competition in the Peripheral T-cell Lymphoma Market

4. Peripheral T-cell Lymphoma Market Dynamics (Key Drivers and Barriers)

5. Peripheral T-cell Lymphoma Market Opportunities

6. Peripheral T-cell Lymphoma Therapeutic Approaches

7. Peripheral T-cell Lymphoma Pipeline Analysis

8. Peripheral T-cell Lymphoma Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the Peripheral T-cell Lymphoma Market

Table of Contents

1. Key Insights

2. Executive Summary

3. Peripheral T-cell Lymphoma Competitive Intelligence Analysis

4. Peripheral T-cell Lymphoma Market Overview at a Glance

5. Peripheral T-cell Lymphoma Disease Background and Overview

6. Peripheral T-cell Lymphoma Patient Journey

7. Peripheral T-cell Lymphoma Epidemiology and Patient Population

8. Peripheral T-cell Lymphoma Treatment Algorithm, Current Treatment, and Medical Practices

9. Peripheral T-cell Lymphoma Unmet Needs

10. Key Endpoints of Peripheral T-cell Lymphoma Treatment

11. Peripheral T-cell Lymphoma Marketed Products

12. Peripheral T-cell Lymphoma Emerging Therapies

13. Peripheral T-cell Lymphoma Seven Major Market Analysis

14. Attribute Analysis

15. Peripheral T-cell Lymphoma Market Outlook (7 major markets)

16. Peripheral T-cell Lymphoma Access and Reimbursement Overview

17. KOL Views on the Peripheral T-cell Lymphoma Market

18. Peripheral T-cell Lymphoma Market Drivers

19. Peripheral T-cell Lymphoma Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

About DelveInsight

Ascites Market is Expected to Showcase a Significant Growth at a CAGR of X% by 2032, as per DelveInsight

DelveInsight’s “Ascites Market Insights, Epidemiology, and Market Forecast – 2032” report delivers an in-depth understanding of Ascites, historical and forecasted epidemiology as well as the Ascites market trends in the United States, EU4 (Germany, France, Italy, Spain), and the United Kingdom, and Japan.

Key Takeaways from the Ascites Market Report

In 2020, the total cases of Ascites due to cirrhosis in the 7MM were ~240,700. Malignant Ascites cases are calculated from ovarian cancer, stomach cancer, breast cancer, and colorectal cancer. In 2020, the number of cases of Ascites from these cancers was ~8,500; ~3,500; ~12,650; and ~10,300, respectively, in the US.
The increase in Ascites Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies in the 7MM.
As per DelveInsight analysis, the Ascites Market is anticipated to witness growth at a considerable CAGR.
The leading Ascites Companies working in the market include Grifols Therapeutics LLC, Sanofi, Regeneron Pharmaceuticals, Sequana Medical N.V, Protgen Ltd, Healthgen Biotechnology Corp, Sichuan Clover Biopharmaceuticals Inc, Movetis, BioVie Inc., Ocelot Bio Inc, Novartis, and others.
Promising Ascites Therapies in the various stages of development include catumaxomab, aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®), M701, Paracentesis, Recombinant Human Serum Albumin, and others.
February 2024:- Wuhan YZY Biopharma Co., Ltd. announced a study of Phase 2 clinical trials for M701 and paracentesis. The phase II study is a controlled, open-label trial designed to assess the effectiveness and safety of M701 intra-peritoneal infusion for controlling malignant ascites in patients with gastrointestinal and ovarian cancer who are also receiving systemic therapy.

Discover which therapies are expected to grab the Ascites Market Share @ Ascites Market Outlook

Ascites Overview

Ascites is a medical condition characterized by the accumulation of fluid in the abdomen. This fluid buildup occurs in the space between the lining of the abdomen and the organs. It's commonly associated with liver disease, particularly cirrhosis, but can also be caused by other conditions such as heart failure, cancer, or infection. Ascites can lead to abdominal swelling, discomfort, and difficulty breathing. Treatment typically involves addressing the underlying cause, reducing fluid intake, medications to remove excess fluid, and sometimes procedures to drain the fluid.

Ascites Epidemiology Insights

The epidemiology section of Ascites offers insights into both historical and current patient populations, as well as forecasted trends across seven major countries. This section aids in understanding the factors behind present and projected trends through analysis of various studies and input from key opinion leaders. Additionally, this portion of the market report provides information on the diagnosed patient pool, trends, and underlying assumptions.

Download the report to understand which factors are driving Ascites Epidemiology trends @ Ascites Epidemiological Insights

Ascites Emerging Drugs

BIV201: BioVie
OCE-205: Ocelot Bio

Ascites Drugs Market

The Ascites Drugs Market is expected to witness substantial growth in the coming years as more targeted therapies receive regulatory approval and enter clinical practice. Additionally, ongoing research efforts aimed at better understanding the molecular mechanisms underlying Ascites signaling in Ascites are likely to uncover new therapeutic targets and further expand treatment options for patients.

Ascites Treatment Market Landscape

The Ascites treatment market landscape has witnessed significant advancements over the past years, with targeted therapies playing a crucial role in improving outcomes for patients. Among these targeted therapies, the emergence of Ascites has garnered attention in the medical community, presenting both challenges and opportunities in treatment strategies.

To learn more about Ascites treatment guidelines, visit @ Ascites Treatment Market Landscape

Ascites Market Outlook

The report's outlook on the Ascites market aids in developing a comprehensive understanding of historical, current, and projected trends. This is achieved by examining the influence of existing Ascites therapies, unmet needs, as well as drivers, barriers, and the demand for advanced technology. This section provides detailed insights into the trends of each marketed Ascites drug and late-stage pipeline therapy. It assesses their impact based on various factors such as annual therapy costs, inclusion/exclusion criteria, mechanism of action, compliance rates, market demand, patient population growth, covered patient segments, anticipated launch year, competition with other therapies, brand value, and input from key opinion leaders. The analyzed Ascites market data are presented concisely through relevant tables and graphs to offer a clear overview of the market dynamics.

Ascites Drugs Uptake

The drug chapter of the Ascites report provides a comprehensive analysis of both marketed drugs and late-stage pipeline drugs for this condition. It delves into the details of clinical trials, pharmacological actions, agreements, collaborations, approvals, patents, and advantages, and disadvantages of each drug, as well as the latest news and press releases related to Ascites.

Major Ascites Companies

Several Ascites Companies working in the market include Grifols Therapeutics LLC, Sanofi, Regeneron Pharmaceuticals, Sequana Medical N.V, Protgen Ltd, Healthgen Biotechnology Corp, Sichuan Clover Biopharmaceuticals Inc, Movetis, BioVie Inc., Ocelot Bio Inc, Novartis, and others.

Learn more about the FDA-approved drugs for Ascites @ Drugs for Ascites Treatment

Scope of the Ascites Market Report

Coverage- 7MM
Ascites Companies- Grifols Therapeutics LLC, Sanofi, Regeneron Pharmaceuticals, Sequana Medical N.V, Protgen Ltd, Healthgen Biotechnology Corp, Sichuan Clover Biopharmaceuticals Inc, Movetis, BioVie Inc., Ocelot Bio Inc, Novartis, and others.
Ascites Therapies- catumaxomab, aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®), M701, Paracentesis, Recombinant Human Serum Albumin, and others.
Ascites Market Dynamics: Ascites Market Drivers and Barriers
Ascites Market Access and Reimbursement, Unmet Needs and Future Perspectives

Discover more about Ascites Drugs in development @ Ascites Clinical Trials Assessment

Table of Content

1. Key Insights

2. Executive Summary of Ascites

3. Competitive Intelligence Analysis for Ascites

4. Ascites: Market Overview at a Glance

5. Ascites: Disease Background and Overview

6. Patient Journey

7. Ascites Epidemiology and Patient Population

8. Ascites Treatment Algorithm, Current Treatment, and Medical Practices

9. Ascites Unmet Needs

10. Key Endpoints of Ascites Treatment

11. Ascites Marketed Products

12. Ascites Emerging Therapies

13. Ascites: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Ascites Market Outlook

16. Ascites Market Access and Reimbursement Overview

17. Ascites KOL Views

18. Ascites Market Drivers

19. Ascites Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Gastroparesis Market is Expected to Showcase a Significant Growth at a CAGR of X% by 2034, as per DelveInsight

DelveInsight's "Gastroparesis Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of the Gastroparesis, historical and forecasted epidemiology as well as the Gastroparesis market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Key Takeaways from the Gastroparesis Market Report

The total Gastroparesis Market Size was found to be around USD 200 million in 2023 in the US, which is further expected to increase by 2034 with the approval of several new therapies in the market.
In 2023, the Gastroparesis market size of the United Kingdom accounted for approximately USD 10 million, which is expected to increase during the forecast period.
As per DelveInsight analysis, the Gastroparesis Market is anticipated to witness growth at a considerable CAGR.
The leading Gastroparesis Companies working in the market include Vanda Pharmaceuticals, Processa Pharmaceuticals, Neurogastrx, CinDome Pharma, and others.
Promising Gastroparesis Therapies in the various stages of development include Velusetrag, tadalafil, PCS12852, Naronapride, and others.
April 2024:- CinDome Pharma Inc.- A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adult Subjects With Diabetic Gastroparesis. The goal of this clinical trial is to evaluate if the study drug CIN-102 (deudomperidone) can help reduce the symptoms associated with diabetic gastroparesis in adult patients.

Discover which therapies are expected to grab the Gastroparesis Market Share @ Gastroparesis Market Outlook

Gastroparesis Overview

Gastroparesis is a condition that affects the stomach muscles, causing them to function improperly or not at all. This condition slows down or stops the movement of food from the stomach to the small intestine. Symptoms can include nausea, vomiting, abdominal pain, feeling full quickly when eating, and bloating. It's often caused by damage to the vagus nerve, which controls the muscles of the stomach. Diabetes, certain medications, and surgery are common causes of gastroparesis. Treatment may include dietary changes, medications to stimulate stomach emptying, and in severe cases, surgery.

Gastroparesis Epidemiology Insights

The epidemiology section of Gastroparesis offers insights into both historical and current patient populations, as well as forecasted trends across seven major countries. This section aids in understanding the factors behind present and projected trends through analysis of various studies and input from key opinion leaders. Additionally, this portion of the market report provides information on the diagnosed patient pool, trends, and underlying assumptions.

Download the report to understand which factors are driving Gastroparesis Epidemiology trends @ Gastroparesis Epidemiological Insights

Gastroparesis Marketed Therapies

GIMOTI (metoclopramide) Nasal Spray: Evoke Pharma

Gastroparesis Emerging Therapies

VLY-686 (tradipitant): Vanda Pharmaceuticals
PCS12852: Processa Pharmaceuticals

Gastroparesis Drugs Market

The Gastroparesis Drugs Market is expected to witness substantial growth in the coming years as more targeted therapies receive regulatory approval and enter clinical practice. Additionally, ongoing research efforts aimed at better understanding the molecular mechanisms underlying Gastroparesis signaling in Gastroparesis are likely to uncover new therapeutic targets and further expand treatment options for patients.

Gastroparesis Treatment Market Landscape

The Gastroparesis treatment market landscape has witnessed significant advancements over the past years, with targeted therapies playing a crucial role in improving outcomes for patients. Among these targeted therapies, the emergence of Gastroparesis has garnered attention in the medical community, presenting both challenges and opportunities in treatment strategies.

To learn more about Gastroparesis treatment guidelines, visit @ Gastroparesis Treatment Market Landscape

Gastroparesis Market Outlook

The report's outlook on the Gastroparesis market aids in developing a comprehensive understanding of historical, current, and projected trends. This is achieved by examining the influence of existing Gastroparesis therapies, unmet needs, as well as drivers, barriers, and the demand for advanced technology. This section provides detailed insights into the trends of each marketed Gastroparesis drug and late-stage pipeline therapy. It assesses their impact based on various factors such as annual therapy costs, inclusion/exclusion criteria, mechanism of action, compliance rates, market demand, patient population growth, covered patient segments, anticipated launch year, competition with other therapies, brand value, and input from key opinion leaders. The analyzed Gastroparesis market data are presented concisely through relevant tables and graphs to offer a clear overview of the market dynamics.

Gastroparesis Drugs Uptake

The drug chapter of the Gastroparesis report provides a comprehensive analysis of both marketed drugs and late-stage pipeline drugs for this condition. It delves into the details of clinical trials, pharmacological actions, agreements, collaborations, approvals, patents, and advantages, and disadvantages of each drug, as well as the latest news and press releases related to Gastroparesis.

Major Gastroparesis Companies

Several Gastroparesis Companies working in the market include Vanda Pharmaceuticals, Processa Pharmaceuticals, Neurogastrx, CinDome Pharma, and others.

Learn more about the FDA-approved drugs for Gastroparesis @ Drugs for Gastroparesis Treatment

Scope of the Gastroparesis Market Report

Coverage- 7MM
Gastroparesis Companies- Vanda Pharmaceuticals, Processa Pharmaceuticals, Neurogastrx, CinDome Pharma, and others.
Gastroparesis Therapies- Velusetrag, tadalafil, PCS12852, Naronapride, and others.
Gastroparesis Market Dynamics: Gastroparesis Market Drivers and Barriers
Gastroparesis Market Access and Reimbursement, Unmet Needs and Future Perspectives

Discover more about Gastroparesis Drugs in development @ Gastroparesis Clinical Trials Assessment

Table of Content

1. Key Insights

2. Report Introduction

3. Executive Summary of Gastroparesis

4. Gastroparesis Market Overview at a Glance

5. Key Events

6. Epidemiology and Market Forecast Methodology

7. Disease Background and Overview

8. Epidemiology and Patient Population

9. Patient Journey

10. Marketed Therapies

11. Emerging Therapies

12. Gastroparesis: Six Major Market Analysis

13. Unmet Needs

14. SWOT Analysis

15. KOL Views

16. Market Access and Reimbursement

17. Appendix

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

About Us